Clinical Trials Browser

Unknown × Breast Neoplasms × pertuzumab × Clear all

NCT05574881 2024-02-26

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT04197687 2023-12-18

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Phase 2 Unknown

Breast Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT05912062 2023-09-29

BiOnHER

Breast Neoplasms, Neoplasms

NCT05036005 2023-04-18

NeoON

Phase 4 Unknown

Breast Neoplasms

NCT03412643 2023-03-06

FB-12

Phase 2 Unknown

Breast Neoplasms

NCT05738993 2023-02-22

A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers

Phase 1 Unknown

Breast Neoplasms

NCT05656079 2022-12-19

easy laugh

Phase NA Unknown

Breast Neoplasms

NCT05483439 2022-08-05

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT01850628 2021-10-05

NSABP Biospecimen Discovery Project

Breast Neoplasms

NCT04717531 2021-06-04

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT04683445 2020-12-24

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Breast Neoplasms

NCT03144947 2020-10-14

IMMUN-HER

Phase 2 Unknown

Breast Neoplasms

NCT04246502 2020-02-05

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT02689921 2018-09-28

NEOADAPT

Phase 2 Unknown

Breast Neoplasms